Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Go back to Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 0.59 +0.02 (3.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.57 | 52 Week High | $9.58 | |||
| Open | $0.55 | 52 Week Low | $2.34 | |||
| Day High | $0.60 | P/E | N/A | |||
| Day Low | $0.53 | EPS | $-0.34 | |||
| Volume | 457,659 | |||||
